RECENT COMMENTS

Baffour Awuah (Male breast cancer): This is a wonderful and provocative subject.Male breast cancers are real issues that has been swept [...]   »Read more

Phil Stewart (Male breast cancer): As a recently diagnosed male breast cancer patinet,it is encouraging to see these groups are promoti [...]   »Read more

Anatolian Society of Medical Oncology (political oncology): Dear editor We read the article on political oncology with deep regret and disappointment. Regret b [...]   »Read more

Fatima Cardoso (Male breast cancer): Dear Bill Thank you very much for your passionate and very important comment. Please understand th [...]   »Read more

Kathy Redmond (Male breast cancer): Dear Bill, Thank you for you comments - at Cancer World we have tried to highlight the fact that me [...]   »Read more

 
 

e-ESO.net

E-eso

Online educational resources Including e-grandrounds, weekly online meetings in collaboration with Nature Reviews Clinical Oncology - CME accredited!

Next live sessions:

GR89 - The role of accelerated partial breast irradiation in the treatment of early-stage breast cancer (in co-operation with OECI)

GR91 - GEJ and gastric cancers: Treatment overview

GR92 - Multiple-myeloma: Is autologous transplantation still standard in younger patients?

The website is supported by an unrestricted educational grant provided by:

Founding sponsor

CancerWorld invites you to visit:

E-eso
European School of Oncology -
ESO Established in 1982, a non-profit organisation exclusively dedicated to increasing the knowledge of health professionals in cancer care.
E-aso
Euro-Arab School of Oncology - is a joint initiative between the Egyptian Ministry of Health and Population and ESO. EASO intends to enhance and support education in the oncology field in all the Arab countries.
 
ECPC
ECPC
Europa Donna
Europa
Donna
Europa Uomo
Europa
Uomo
EONS
EONS
SIOG
SIOG
The challenge Fund
The
Challenge
Fund
Seno network
SenoNetwork
CancerWorld is a pioneering initiative of the European School of Oncology financially supported through Sharing Progress in Cancer Care, a collaborative programme between ESO and Amgen, AstraZeneca, Eli Lilly, GlaxoSmithKline, Merck and Novartis.